Immune Profiling Evaluation of Newly Diagnose Multiple Myeloma (NDMM) Transplant Eligible (TE) Patients Treated with Daratumumab, Cyclophosphamide, Thalidomide and Dexamethasone. Preliminary Results

被引：1
|
作者：
Santos, Allan de Souza
Santos, Herbert Henrique de Melo
Salvino, Marco Aurelio
Silva, Sarah Queiroz
Lucas, Larissa Ferreira
Almeida, Alessandro de M.
Santos, Mariane Melo
Santos, Juliana Andrade
Hungria, Vania T. M.
Arruda, Maria da Gloria B.
Torres, Alex
Crusoe, Edvan De Queiroz
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-141438
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Real-world Data on the Use of Subcutaneous Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Patients With Newly Diagnosed Multiple Myeloma
    Hungria, Vania T. M.
    Moura, Fernanda Lemos
    Soares, Paulo
    Lima, Juliana Souza
    Ricci, Lisa Aquaroni
    Nucci, Fabio Moore
    Oliveira Ribeiro, Eduardo Flavio
    Crusoe, Edvan de Queiroz
    Lima, Marinus de Moraes
    Pessoa de Magalhaes Filho, Roberto Jose
    Arrais-Rodrigues, Celso
    Bhaumik, Amitabha
    Parekh, Trilok
    Borgsten, Fredrik
    Carson, Robin
    Trufelli, Damila C.
    Costa, Abel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S230 - S230
  • [22] A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
    Moreau, Philippe
    Attal, Michel
    Facon, Thierry
    Caillot, Denis
    Lenain, Pascal
    Benboubker, Lofti
    Lam, Annette
    Krotneva, Stanimira
    Proskorovsky, Irina
    Kampfenkel, Tobias
    Vanquickelberghe, Veronique
    Cote, Sarah
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E200 - E201
  • [23] Daratumumab (DARA) plus lenalidomide/bortezomib/dexamethasone (RVd) in Black patients with transplant-eligible newly diagnosed multiple myeloma (NDMM): an updated subgroup analysis of GRIFFIN
    Nooka, Ajay
    Kaufman, Jonathan
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah
    Anderson, Larry
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas
    Usmani, Saad
    Richardson, Paul
    Voorhees, Peter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S155 - S156
  • [24] Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
    Anderson, Larry D., Jr.
    Kaufman, Jonathan L.
    Laubach, Jacob P.
    Sborov, Douglas W.
    Reeves, Brandi
    Rodriguez, Cesar
    Chari, Ajai
    Silbermann, Rebecca W.
    Costa, Luciano J.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Voorhees, Peter M.
    Richardson, Paul G.
    BLOOD, 2021, 138
  • [25] Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) plus bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study.
    Hulin, Cyrille
    Moreau, Philippe
    Attal, Michel
    Belhadj, Karim
    Benboubker, Lotfi
    Caillot, Denis
    Facon, Thierry
    Garderet, Laurent
    Kuhnowski, Frederique
    Stoppa, Anne-Marie
    Kolb, Brigitte
    Tiab, Mourad
    Sonneveld, Pieter
    Jie, Kon-Siong
    Westerman, Matthijs
    Pei, Lixia
    Kampfenkel, Tobias
    De Boer, Carla
    Vermeulen, Jessica
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Real-World Data on the Daratumumab Plus Bortezomib, Thalidomide and Dexamethasone Followed by Lenalidomide Maintenance for Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients
    Crusoe, Edvan de Queiroz
    Ribeiro, Glaciano
    Moura, Fernanda
    Costa, Abel
    Aranha, Milton
    Bittencourt, Rosane
    Ribeiro, Eduardo
    Neto, Jorge
    Cunha, Rafael
    Mattos, Ederson
    Braga, Walter
    Lima, Juliana Souza
    Gusmao, Breno
    Lopes, Danielle Ovigli
    Berg, Luiza
    Souto, Joao
    Maiolino, Angelo
    Hungria, Vania T. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S223 - S223
  • [27] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Nooka, Ajay K.
    Kaufman, Jonathan L.
    Rodriguez, Cesar
    Jakubowiak, Andrzej
    Efebera, Yvonne
    Reeves, Brandi
    Wildes, Tanya
    Holstein, Sarah A.
    Anderson, Larry D., Jr.
    Badros, Ashraf
    Shune, Leyla
    Chari, Ajai
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Bartlett, J. Blake
    Vermeulen, Jessica
    Lin, Thomas S.
    Richardson, Paul G.
    Voorhees, Peter
    BLOOD CANCER JOURNAL, 2022, 12 (04)
  • [28] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
    Ajay K. Nooka
    Jonathan L. Kaufman
    Cesar Rodriguez
    Andrzej Jakubowiak
    Yvonne Efebera
    Brandi Reeves
    Tanya Wildes
    Sarah A. Holstein
    Larry D. Anderson
    Ashraf Badros
    Leyla Shune
    Ajai Chari
    Huiling Pei
    Annelore Cortoos
    Sharmila Patel
    J. Blake Bartlett
    Jessica Vermeulen
    Thomas S. Lin
    Paul G. Richardson
    Peter Voorhees
    Blood Cancer Journal, 12
  • [29] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
    Tsukada, Nobuhiro
    Ikeda, Masahiro
    Shingaki, Sumito
    Miyazaki, Kanji
    Meshitsuka, Sosuke
    Abe, Yu
    Yoshiki, Yumiko
    Suzuki, Kenshi
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
  • [30] Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.
    Rodriguez-Otero, Paula
    Moreau, Philippe
    Dimopoulos, Meletios Athanasios
    Beksac, Meral
    Perrot, Aurore
    Broijl, Annemiek
    Gay, Francesca
    Mina, Roberto
    van de Donk, Niels W. C. J.
    Schjesvold, Fredrik
    Delforge, Michel
    Einsele, Hermann
    Spencer, Andrew
    Lonergan, Sarah
    Vieyra, Diego
    Sitthi-Amorn, Anna
    Carson, Robin L.
    Blade, Joan
    Boccadoro, Mario
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345